Recent studies have highlighted the interconnectedness of Aβ accumulation, tau aggregation, and axonal transport dysfunction, which suggests the potential for targeting axonal function as a therapeutic approach for AD and tauopathies. The gene discussed is MAPT; the disease is tauopathy.